Lyvgen Biopharma Holdings Limited
Clinical trials sponsored by Lyvgen Biopharma Holdings Limited, explained in plain language.
-
New drug combo shows promise for rare sarcoma
Disease control CompletedThis study tested a new drug (LVGN6051) combined with an existing drug (anlotinib) in 39 adults with advanced soft tissue sarcoma that had not responded to other treatments. The main goals were to check safety and find the best dose, and to see if the combination could shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated May 26, 2026 08:37 UTC
-
New drug combo targets tough cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called LVGN6051, given alone or with the immunotherapy Keytruda, in 105 adults with advanced or spreading cancers. The main goal was to find safe doses and check for side effects. The study is complete, but results are not yet available.
Phase: PHASE1 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New antibody combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug called LVGN7409, which boosts the immune system to fight cancer. It was given alone or with other immune-boosting drugs to 66 adults with advanced cancers that had stopped responding to other treatments. The main goals were to find safe do…
Phase: PHASE1 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated May 22, 2026 14:03 UTC